Edgar Filing: JOYCE R TODD - Form 4

Check this box if no longer subject to Section 16. SECURITIES SECURITIES NUMBERSHIP OF Section 16. SECURITIES NUMBERSHIP OF SECURITIES NUMBERSHIP SECURITIES NUMBERSHIP									3235-0287 January 31, 2005 average irs per		
(Print or Type R	lesponses)										
1. Name and Address of Reporting Person <u>*</u> JOYCE R TODD			2. Issuer Name and Ticker or Trading Symbol WATSON PHARMACEUTICALS INC [WPI]				-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) C/O WATSON PHARMACEUTICALS, INC., 311 BONNIE CIRCLE			3. Date of Earliest Transaction (Month/Day/Year) 10/30/2009					Director 10% Owner X Officer (give title Other (specify below) below) Sr Vice Pres. & CFO			
				endment, Date Original onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)		Zip)	Table	I - Non-De	erivative S	ecuri	ties Ac	Person quired, Disposed o	f or Beneficia	llv Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	n Date 2A. Deemed		3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or			r)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership	-	
Common Stock, par value \$0.0033	10/30/2009			A	6,800 (1)	(D) A	\$ 0	24,911 <u>(2)</u>	D		
Common Stock, par value \$0.0033								6,207	I	Trust	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: JOYCE R TODD - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
FB	Director	10% Owner	Officer	Other			
JOYCE R TODD C/O WATSON PHARMACEUTICALS, INC. 311 BONNIE CIRCLE CORONA, CA 92880			Sr Vice Pres. & CFO				
Signatures							

Signatures

/s/R. TODD 10/30/2009 JOYCE

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These restricted shares of common stock, par value \$0.0033, were issued pursuant to the provisions of the Second Amendment and (1) Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc. and will vest 50% on October 30, 2011 and 50% on

- October 30, 2013.
- Includes shares of restricted stock issued pursuant to the Second Amendment and Restatement of the 2001 Incentive Award Plan of (2)Watson Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.